Results
Beta Drugs Q4 FY26 Revenue Up 7.6%, EBITDA Margins Expand
Beta Drugs reported FY26 revenue growth to INR396 crore with EBITDA margins expanding to 22.57% from 21.1%.
The company acquired 66.1% stake in Nivian Lifesciences for INR69.4 crore to enter the IVF t
